Pfizer continues recalls of menopause drug Duavee on faulty packaging concerns

Pfizer sign
(Tracy Staton) Pfizer's menopause drug recall comes as consumers worry about the quality of their drugs during the COVID-19 pandemic. (Pfizer)

Consumers are on edge as the COVID-19 pandemic casts doubts on the quality of drugs reaching shelves around the world. On U.S. shores, experts say those issues are warranted—and a wave of Pfizer recalls for menopause drug Duavee won't help build confidence. 

Pfizer voluntarily recalled two batches of Duavee––marketed as Duavive abroad––from U.K. shelves after identifying faulty packaging that may have reduced the drug's efficacy, the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) said Monday.

Pfizer launched the recall after manufacturers identified a flaw in the drug's foil laminate pouch that introduced oxygen and lowered the dissolution rate of active pharmaceutical ingredient bazedoxifene acetate, the MHRA said.

Featured Webinar

How to Streamline Your Clinical Research Organization's Processes End to End

Learn how implementing one platform leads to data consistency and ultimately facilitate faster clinical trials while reducing overall trial costs, leave behind spreadsheets and home-grown tools for a predictable trial and the ability to forecast unit delivery resulting in the optics you need to ensure a successful trial, and hear experts share industry trends of what is affecting the Clinical Research Organization industry today.

The U.K. recalls comes just weeks after Pfizer voluntarily withdrew 11 lots of Duavee in the U.S. at the wholesaler level and two in Canada in late May, a Pfizer spokeswoman said.

The two recalled U.K. batches of 28-pack Duavive tablets expire in September 2020 and August 2021. Any remaining consumer stock should be quarantined and sent back to Pfizer for reimbursement, according to the MHRA. 

RELATED: Are metformin recalls just the start? Valisure CEO calls for independent foreign drug tests amid COVID-19

In a recall notice dated May 20, Health Canada said Pfizer Canada would pull two affected lots of Duavive for issues with bazedoxifene dissolution.

The agency classified the recall as a Class II hazard, meaning "a situation in which the use of, or exposure to, a product may cause temporary adverse health consequences or where the probability of serious adverse health consequences is remote."

Duavee received an FDA approval in 2013 as a treatment for symptoms associated with menopause and osteoporosis.

RELATED: FDA pushes metformin recalls for 5 drugmakers after carcinogen contamination

Pfizer's recalls come as consumers grow increasingly concerned about drug quality during the COVID-19 pandemic.

Last week, independent testing laboratory Valisure's CEO David Light testified to U.S. senators that the pandemic would likely put a strain on the FDA's ability to adequately test the quality of drugs produced in foreign plants.

The FDA has maintained an effective ban on foreign inspections since March, only venturing inspectors into foreign manufacturing facilities for high-priority check-ins.

Meanwhile, the FDA in early June asked five drugmakers to voluntarily withdraw their versions of commonly used diabetes drug metformin off shelves after the agency identified high levels of NDMA contamination in tested lots.

Suggested Articles

Three facts about how distributors are managing in-demand inventory.

Novartis’ latest campaign with a celebrity dance partner asks people to bust a move to raise awareness around sickle cell anemia and therapy Adakveo.

Purdue has reached an $8 billion settlement with the U.S. government to settle criminal and civil charges for its role in the U.S. opioid crisis.